KedarShirishKirtaneMD

Physician

Overview of Dr. Kirtane

Kedar Kirtane, MD, is an oncology specialist based in Tampa, FL. He completed his medical education in 2012 at the University of Florida College of Medicine, followed by a residency in Internal Medicine at Duke University Hospital from 2012 to 2015. He further specialized with a fellowship in Hematology and Medical Oncology at the University of Washington from 2015 to 2018. Dr. Kirtane has contributed to several publications in the field, including research on pembrolizumab in head and neck cancer, T-cell responses to neoantigen therapy, and the integration of multidisciplinary cancer care. His work has been cited by other professionals, reflecting his active engagement in oncology research.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(929) 605-1684

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2015 - 2018
Duke University HospitalResidency, Internal Medicine, 2012 - 2015
University of Florida College of MedicineClass of 2012

Certifications & Licensure

FL State Medical License 2018 - 2026
WA State Medical License 2015 - 2019
NC State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

The patient and caregiver experience of CAR T-cell therapy: A qualitative analysis.
Maija Reblin, Irene Liang, Djin L Tay, Kedar Kirtane, Dana Ketcher
Journal of Psychosocial Oncology. 2025-01-30
Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer.
Benjamin Lee, Sarah S Chehab, Wenyi Fan, Michael J Schell, Kedar S Kirtane
Journal of Oncology Pharmacy Practice. 2024-12-01
2 citations
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman
Cancer Discovery. 2024-11-01

Lectures

Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/met...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

I AM INCLUDED: 8 Best Practices for Sites to Drive More Inclusive Clinical TrialsDecember 13th, 2024
Getting Help for Sexual Health Problems When You Have Head and Neck Cancer: An Expert Q&AApril 14th, 2022
Moffitt Doctors Say They're Closing in on Cures for Certain Common CancersFebruary 8th, 2022